Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
Status:
Completed
Trial end date:
2017-04-13
Target enrollment:
Participant gender:
Summary
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with
stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise
time during an exercise treadmill test.